Background: Increased levels of the inflammatory biomarker high sensitivity C-reactive protein (hsCRP) predict cardiovascular events, even when cholesterol levels are low. As statins lower hsCRP as well as cholesterol, we hypothesized that individuals with elevated hsCRP but without hyperlipidemia might benefit from statin therapy. Methods: In an investigator-initiated, multi-national, randomized, double-blind, placebo-controlled trial conducted at 1,300 sites in 26 countries, 17,802 apparently healthy men and women with LDL Ͻ 130 mg/dL and hsCRP Ͼ 2 mg/L were randomly allocated to rosuvastatin 20 mg daily or to placebo and then followed for the occurrence of a first major cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death). Median levels of LDL, HDL, TG, and hsCRP at study entry into JUPITER were 108 mg/dL, 49 mg/dL, 118 mg/dL, and 4.3 mg/L, respectively. The JUPITER trial includes 6,801 women and 25 percent of the randomized cohort are of minority background. Results: Based on a range of expected event rates in the placebo group, power calculations for the JUPITER trial suggested that a sample size between 15,000 and 18,000 participants would be needed to detect a relative risk reduction of 25 percent, assuming an average follow-up period of 3 to 4 years and a 5 percent drop-out rate. However, on March 29, 2008, the Independent Data and Safety Monitoring Board of the JUPITER trial unanimously recommended early termination after a mean follow-up of only 2 years due to the emergence of an unequivocal benefit of rosuvastatin on the trial primary endpoint in the absence of any substantive safety hazard. Conclusions: Formal presentation of the JUPITER trial results will be made for the first time at the AHA meeting in November 2008.
10,012 men and 2052 women; average age 64 (SD 9) years. At randomization, 33% reported coronary revascularisation, 7% cerebrovascular disease, 11% diabetes and 42% treated hypertension. Allocation to simvastatin 80mg daily yielded further LDL-reductions of 0.5 mmol/L at 2 months and 0.3 mmol/L at 5 years. Primary outcome is major vascular event (MVE), which is defined as non-fatal MI or coronary death, any stroke, or any arterial revascularisation. During median follow-up of 7 years, about 3000 participants have had MVEs (1500 non-fatal MI or coronary death; 500 strokes;1000 revascularisations), 1300 have developed cancer and 2000 have died (1000 vascular and 1000 non-vascular). Conclusion: SEARCH is the largest randomized trial to assess the effects of more intensive statin therapy directly. The large numbers of vascular and non-vascular events during the prolonged treatment period provide good statistical power to detect plausible further reductions in major vascular events, while also providing a reliable assessment of the safety of more intensive LDL-lowering. Final results of SEARCH would be presented during the AHA meeting and discussed in the context of the other randomized evidence. The implications of these findings are important because they will help to resolve the existing uncertainty about the value of more intensive cholesterol-lowering therapy.
Background: Rivaroxaban is a novel oral direct Factor Xa inhibitor that has been effective in prevention of venous thromboembolism after major orthopedic surgery. The efficacy and safety of rivaroxaban following acute coronary syndromes (ACS) has not previously been evaluated. Methods: ATLAS ACS-TIMI 46 is a phase II, international, randomized, double-blind, placebo-controlled, dose-escalation study conducted in post-ACS patients to evaluate the efficacy and safety of rivaroxaban in combination with aspirin (Stratum 1) or aspirin ϩ thienopyridine (Stratum 2). Patients received rivaroxaban (total daily dose: 5, 10, 15, or 20 mg as a once-daily or twice-daily regimen) or placebo and were followed for 6 months. Results: A total of 3,491 subjects (760 in Stratum 1; 2,731 in Stratum 2) were randomized at 297 sites in 27 countries. The final visit for the last patient will be conducted by September 21, 2008 . The mean age is 57 years (range: 24 -88), 77% are male, 19% have diabetes, and 21% had a prior MI. On presentation, 52% had a STEMI; 63% of subjects underwent PCI for their index event. Subjects are being followed for efficacy (death, MI, stroke, and severe recurrent ischemia requiring revascularization) and safety (TIMI major and minor bleeding and bleeding requiring any medical attention) events. An independent clinical events committee is adjudicating all components of the endpoints. Efficacy and safety results will be presented. Conclusion: ATLAS ACS-TIMI 46 is a randomized clinical trial investigating the relative risks and benefits of the addition of the novel anticoagulant rivaroxaban to either single or dual antiplatelet therapy in a contemporary cohort of post-ACS patients.
Drug-Eluting and Bare Metal Stenting in Patients with Diabetes Mellitus: Results from the Mass-DAC Registry
Laura Mauri, Pallav Garg, Brigham and Women's Hosp, Boston, MA; Treacy S Silbaugh, Robert E Wolf, Katya Zelevinsky, Ann F Lovett, Harvard Med Sch, Boston, MA; Manu R Varma, Zheng Zhou, Brigham and Women's Hosp, Boston, MA; Sharon-Lise T Normand; Harvard Sch of Public Health, Boston, MA Background: Patients with diabetes mellitus (DM) are at high risk of restenosis, myocardial infarction (MI) and cardiac mortality following coronary stenting and the long-term safety of drug-eluting stents (DES) relative to bare metal stents (BMS) in DM is uncertain. We report on a large consecutive series of patients with DM followed for 3 years after DES and BMS from a regional contemporary US practice with mandatory reporting. Methods: All adults with DM undergoing percutaneous coronary intervention (PCI) with stenting between April 1, 2003 and September 30, 2004 at all acute care non-federal hospitals in Massachusetts (MA) were identified from a mandatory state database. According to index admission stent type, patients were classified as DES treated if all stents were drug-eluting and BMS-treated if all stents were bare metal; patients treated with both types of stents were excluded from the primary analysis. Mortality rates were obtained from vital statistics records with complete 3 year follow up, and MI and revascularization rates, from the state database with 2 years follow up on the entire cohort. Risk-adjusted mortality, MI, and revascularization differences (DES-BMS) were estimated using propensity score matching, based on clinical, procedural, hospital, and insurance information collected at the index admission. Results: DM was present in 5051 patients (29% of the population) treated with DES or BMS during the study. Patients with DM were more likely to receive DES than BMS (66.1% vs. 33.9%, pϽ0.001). The unadjusted cumulative incidence of mortality at 3 years was 14.4% in DES vs. 22.2% in BMS (pϽ0.001). Based on propensity score analysis of 1:1 matched DES vs. BMS patients (1476 DES:1476 BMS), the risk-adjusted mortality at 3 years was 17.5% vs. 20.7% (risk difference -3.2% [-6 .0%, -0.4%], pϭ0.02) and MI and target vessel revascularization rates at 2 years were 10.8% vs. 14.1% (-3.3% [-5 .7%, -1.0%], pϭ0.006) and 12.7% vs. 17.1% (-5.4% [-8.1%, -2 .6%], pϽ0.001), respectively. Conclusion: In a real-world diabetic patient population with mandatory reporting and follow-up, DES were associated with reduced mortality, MI, and revascularization rates at long-term follow-up compared with BMS. Background: Randomized trials have trials have demontrated a benefit of an invasive management strategy in patients with non-ST segment elevation acute coronary syndromes (ACS). However, the optimal timing of when to intervene in these patients has not been determined. Study Design: A prospective, muti-center, muti-national, randomized trial comparing early versus delayed invasive strategies in patients with high risk ACS. Hypothesis: An early invasive strategy will be superior to a delayed invasive strategy in reducing death, MI or stroke. Inclusion Criteria: Patients presenting with symptoms/signs compatible with UA/NSTEMI and within 24 hours from symptom onset and at least two of the following 3 criteria: AgeϾ60, Elevated Troponin T or I or CKMB or ischemic ECG changes. Sample Size: Approximately 3000 patients from 100 centers in 30 countries Randomized Treatments: Early Invasive Strategy defined as coronary angiography as soon as possible (and no later than 24 hours) followed by anatomy-driven intervention (PCI or CABG). Delayed Invasive Strategy defined as coronary angiography after 36 hours followed by anatomy-driven intervention (PCI or CABG). Primary Outcome: Composite of Death, Myocardial Infarction or Stroke at 6 months Study Power: Assuming a control event rate of 12% in the delayed invasive group, the study will have 80% power to detect a 27% relative risk reduction. Progress: The last patient will be included in early July 2008. Will the last followup visit will be in mid October and we will finalize the data in early November for presentation at the AHA meeting. Background: Stent thrombosis represents a major pitfall of percutaneous coronary revaszcularization. Enhanced platelet reactivity inhibition has been associated with a reduction in thrombotic events in patients undergoing percutaneous coronary intervention (PCI). We aimed to investigate the impact of tailored clopidogrel loading dose (LD) according to platelet reactivity monitoring, using the VASP index, on definite stent thrombosis (DST) in patients undergoing PCI. Methods: A multicenter prospective randomized study included all patients with clopidogrel low response after a 600mg LD of clopidogrel undergoing PCI. The control group included 214 patients and the VASP guided group 215 patients who received up-to 3 additional 600mg clopidogrel LD to obtain a VASP index Ͻ50% before PCI. The primary end-point was the rate of DST at one month. Secondary end-points were the rate of major adverse cardiovascular events (MACE) and of bleeding. Results: Despite 2400 mg LD of clopidogrel 8% of the patients randomized to the VASP-guided group remained low-responders. The rate of definite stent thrombosis was significantly lower in the VASP-guided group compared to the control group (0.5 vs 4.2 %; pϽ0.01). Fifty percent of patients who had stent thrombosis had GP IIb/IIIa inhibitors at the time of the index procedure. The rate of MACE was also significantly lower in the VASP-guided group (0.5 vs 8.9%; pϽ0.001). There was no difference in the rate of bleeding (control vs VASP guided group 2.8 vs 3.7%; pϭ0.8). Conclusion: Tailored clopidogrel loading dose according to platelet reactivity monitoring decreased the rate of early definite stent thrombosis after PCI without increased bleeding.
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Stent Thrombosis
Background: Aerobic exercise training in heart failure (HF) patients (pts) improves symptoms, exercise capacity, and quality of life (QOL). HF guidelines recommend exercise training for stable outpts. Prior studies have not been powered to evaluate exercise training and clinical outcomes. HF-ACTION tested the hypothesis that aerobic exercise training in HF pts will improve clinical outcomes. Methods: HF-ACTION was a multicenter, randomized (1:1) controlled trial of usual care ϩ exercise training vs. usual care alone in stable pts with LVEF Յ35% and NYHA class II-IV HF. Key exclusions were regular exercise, cardiac devices limiting target heart rate, and exercise test results indicating training may be unsafe. The intervention included 36 supervised training sessions (goal 3 times/week). Exercise intensity was increased based on heart rate reserve and rate of perceived exertion. Pts were then provided with home equipment and encouraged to exercise at home 5 times/week. The usual care arm received the ACC/AHA recommendation to perform 30 minutes of moderate intensity activity most days of the week, but no additional instructions for exercise were given. Adherence was measured for the exercise training arm, and physical activity was recorded for the usual care group. Pts were followed for at least 1 year. The primary endpoint was the composite of all-cause mortality and all-cause hospitalization. The study was designed to achieve 90% power to detect an 11% reduction in the 2 year primary event rate, accounting for nonadherence and crossover. Secondary endpoints included individual components of the primary endpoint, cause-specific mortality/morbidity, cardiopulmonary fitness measures, QOL, and cost. Results: Between 4/03 and 2/07, 2331 pts were enrolled. Median age was 59 years, 28% were women, and 40% were minorities. Mean LVEF was 25%, and 51% had an ischemic etiology. Baseline treatments included ACE-inhibitor or angiotensin receptor blocker, 94%; beta blocker, 95%; ICD or bi-ventricular pacemaker, 45% overall and 53% in ischemic pts. Median follow-up was 2.5 years. Primary endpoint data will be presented. Conclusions: HF-ACTION will reveal the effect of exercise training on important clinical outcomes, including survival, in pts with systolic HF. Background: 50% of heart failure (HF) patients (Pts) have preserved ejection fractions (HFPEF), yet no treatment has improved their clinical outcomes. Hypothesis: I-PRESERVE tested the hypothesis that the angiotensin receptor blocker (ARB) irbesartan reduces the occurrence of the primary composite endpoint of death, non-fatal MI, or stroke, hospitalization for HF, unstable angina, or cardiac arrhythmia. Secondary endpoints include HF mortality or hospitalization, all-cause and cardiovascular mortality, non-fatal MI or stroke, and quality of life. Methods: I-PRESERVE is a randomized, double-blind, placebo-controlled trial. It was continued until 1,440 primary events occurred, providing 90% power to detect a 14.5% relative risk reduction of the primary endpoint with a 2-sided ␣ϭ0.05 in an intention to treat analysis of time to first event. Pts with LVEF Ն45% and Ն60 years with NYHA class II-IV CHF symptoms and a HF admission within 6 months or NYHA III-IV symptoms and supportive evidence for HFPEF were eligible for enrolment. Major exclusions were prior LVEF Ͻ40%, primary valvular or cardiomyopathic disease, uncontrolled hypertension, and comorbid conditions that might limit life expectancy to Ͻ5 years or cause symptoms that mimic HF. Patients taking an ARB were excluded, and only 1/3 Pts could be on an ACE inhibitor at entry. Irbesartan or matching placebo was initiated at 75 mg daily and uptitrated to 150 mg and 300 mg at 2 week intervals as tolerated. Results: Commencing in June 2002, 4,128 Pts (mean EF 59Ϯ9%; mean age 72 years; 60% women) were randomized. 88% had a history of hypertension (mean entry BP 136/89), 29% atrial fibrillation, 27% diabetes, 23% prior MI, and 10% stroke or TIA. Baseline medications included diuretics (84%), beta-blockers (59%), calcium blockers (40%), ACE inhibitors (25%), spironolactone (15%). The study ended on April 17, 2008, when an estimated 1,440 primary endpoints had occurred. The I-PRESERVE results are being presented for the first time at this meeting. Conclusion: I-PRESERVE is the largest trial conducted in Pts with HFPEF. It will determine whether irbesartan is effective in reducing the major cardiovascular events that affect this population and provide novel insight into the clinical course of this syndrome. Thirty-one centers from 7 European countries participated in this randomized, double-blinded, placebo-controlled, parallel group, multicenter phase II study evaluating the efficacy and safety of two doses of interferon beta-1b (IFNB-1b) versus placebo in patients with biopsy-proven chronic viral cardiomyopathy (CVC). The diagnosis of CVC for the target population was based on the existence of chronic heart failure and the presence of adenovirus, enterovirus, and/or parvovirus in endomyocardial specimens obtained by endomyocardial biopsy. In the three treatment arms, patients received 2 different doses of IFNB-1b or placebo, given subcutaneously every other day for 24 weeks. The primary variable was the presence of adenovirus, enterovirus and/or reduction in parvovirus in endomyocardial biopsies taken 12 weeks Ϯ 14 days after the end of treatment. For the parvovirus group, virus-elimination or load reduction was assessed using a quantitative assay by defining a suitable threshold value. Secondary efficacy variables were change in NYHA functional class, 6-minute walking test, single clinical symptoms, quality of life, left ventricular ejection fraction (LVEF) at rest and on exertion, echocardiographic parameters, inflammatory state in endomyocardial biopsies, composite clinical endpoint, wedge pressure and mean pulmonary artery pressure. 368 patients were screened for enrollment and 143 patients were randomized to treatment. 131 patients completed the study. Compared to placebo, virus elimination and/or virus load reduction were significantly higher in the IFNB-1b groups as compared with Placebo (odds ratio 2.33, 2-sided pϭ0.049), without significant differences between both interferon groups. IFNB-1b treatment was associated with beneficial effects on NYHA functional class (pϭ0.013 at follow-up week 12), improvement in quality of life (Minnesota total score) (pϭ0.032 at follow-up week 24) and patient global assessment (follow-up week 12 to follow-up week 24) (pϭ0.039). There were no safety concerns. The results demonstrate that IFNB-1b treatment leads to an effective virus clearance or reduction of virus load with favorable effects on quality of life, NYHA functional class and patient global assessment in patients with CVC. strong prognosticator in AHF patients. Methods: The BACH Multinational Trial was a prospective, 15-center international multiple serum biomarker study of 1641 patients presenting to the emergency department (ED) with shortness of breath (SoB). The primary endpoint was to test for superiority of MRproADM vs BNP to predict 90-day mortality. Secondary endpoints included to test for superiority vs NTproBNP, and to perform these tests in all patients presenting with SoB to the ED. Physicians were blinded to MRproADM values. The gold standard diagnoses of HF were established by 2-3 cardiologists. Clinical lab troponin values (TnI or TnT) were judged as elevated if above the local normal range. Results: Of 1641 BACH patients, 568 (34.6%) had a diagnosis of HF. Of these, 65 (11.4%) died within 90 days. The prognostic accuracy of MRproADM (73.1% correct) was superior to BNP (60.6%, pϽ0.001) and NTproBNP (63.0%, pϽ0.001). These findings held true for all 1641 enrolled patients (130 deaths) and for the 477 AHF patients admitted to the hospital (all pϽ0.001), satisfying the primary and secondary prognostic endpoints of the BACH Multinational Trial. The hazard ratios (HRs) comparing the 2nd, 3rd, and 4th ADM quartiles to the first in all 1641 patients were 7.4 (95%CI 2.2-24.8, pϭ0.001), 10.7 (3.3-35.0, pϽ0.001), and 26.8 (9.5-85.1, pϽ0.001), respectively. Troponin values were available in 511 of 568 HF patients, and in 107 (20.9%) patients they were elevated. As shown below, MRproADM significantly predicted 90-day mortality in Cox analyses independently of either BNP or NTproBNP in models both with and without troponin. Conclusions: MRproADM is superior to BNP and NTproBNP, regardless of troponin levels, for predicting 90-day mortality in patients with shortness of breath and acute heart failure. Background: Warfarin anticoagulation reduces thromboembolic complications in patients with atrial fibrillation and mechanical heart valves but effective management is complex and it is common for patients to be above or below target INR range. Point-of-care INR devices can be used by patients in their homes. By allowing greater testing frequency and patient involvement, such home testing has the potential to improve clinical outcomes. We tested whether weekly home INR testing will reduce the risk of stroke, major bleed and death compared to monthly clinic testing. Methods: Patients on warfarin due to mechanical heart valves or atrial fibrillation were trained in the use of the ITC ProTime® POC-INR device and tested for competency after 2 to 4 weeks. Subjects competent in device use were randomized to either weekly home testing or monthly clinic testing. In a substudy about 100 subjects home tested twice a week and about 100 home tested once a month. The primary endpoint was time to first event: stroke, major bleed, or death. Sample size was based on an estimated composite annual event rate of 5.5% in the clinic testing arm, which would be reduced to 3.75% in the home testing arm. Secondary outcomes included time in target range, myocardial infarctions, non-stroke thromboembolisms, minor bleeds, patient satisfaction, competence and compliance with PST, anticoagulation related quality of life, and cost effectiveness. Results: 3,745 subjects at 28 VA Medical Centers were enrolled in Part 1 and 2,922 subjects (78%) were randomized into Part 2. Indications for warfarin were mechanical heart valve (23%) and atrial fibrillation (83%). Subjects were followed for 2.0 to 4.75 years, with 8,730 patient-years (PY) of follow-up: 4,495 PY in the home testing arm and 4,235 PY in the clinic arm. Time to first reported event was not significantly improved in the home testing arm (hazard ratio ϭ 0.875 with 95% confidence interval 0.741 to 1.033; pϭ 0.11 by log-rank test) for the primary endpoint nor any of its three components (stroke, major bleed, death). Similar analyses to be conducted on adjudicated endpoints may indicate different findings. Time in target range was higher in the home testing group (65.9% vs. 62.2%, pϽ0.001), as was patient satisfaction (47.7 vs. 49.1, pϽ0.02; lower score means higher satisfaction). Conclusions: Compared with monthly clinic INR testing, weekly home INR monitoring may not improve the aggregate outcome of stroke, major bleed, or death, to the extent previously suggested. However, such monitoring does appear to improve time in target range and patient satisfaction with anticoagulation therapy. The results support the notion that home testing is an acceptable alternative to routine care, and may be preferable when patient access to routine care is difficult (e.g., due to disability or geographic distance). Background: Patients with heart failure have reduced exercise tolerance, resulting in lowered health-related quality of life. Exercise training may improve physical functioning, reduce symptoms, and improve health-related quality of life, but in previous studies, the effects of exercise training on health-related quality of life have been inconsistent. The NHLBI-funded Heart Failure: A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) study was designed to test the hypothesis that exercise training in heart failure patients will improve clinical outcomes. A secondary goal was to examine the impact of exercise training on health-related quality of life. Methods: HF-ACTION was a large multicenter, randomized (1:1), controlled trial (RCT) in medically stable patients with LVEF Յ35% and NYHA class II-IV heart failure. Patients were randomized to either usual care plus aerobic exercise training, consisting of 3 months of supervised aerobic exercise training followed by instructed home-based-training, or to usual care alone. The primary health-related quality of life endpoint was patient-reported health status, measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ was administered at baseline, at 3 month intervals during clinic visits for the first year, and annually thereafter for up to 4 years. We will examine treatment group effects and estimate mean differences in the KCCQ Overall Summary Scale and key subscales (Physical Limitations, Symptoms, Social Limitations, and Health-related Quality of Life) using linear mixed models following the intent-to-treat principle. Results: 2331 patients were enrolled. Median age was 59 years, 28% were women, and 40% were minorities. Mean LVEF was 25%, and 51% had an ischemic etiology. Median follow-up was approximately 2.5 years. Baseline clinical characteristics (peak VO 2 ) and KCCQ scores will be presented, as will results from the analysis of change in overall KCCQ and its subscales by treatment arm. Conclusions: The HF-ACTION RCT results from a large number of patients will address the effect of aerobic exercise training on health status in patients with systolic heart failure, an outcome of primary importance from patients' perspectives. Background: Rosiglitazone (RSG), a member of the thiazolidinedione class of peroxisome proliferator-activated receptor-␥ agonists, has effects on insulin resistance and other cardiovascular risk factors that may favorably affect progression of coronary atherosclerosis. Study Design: The APPROACH trial is a prospective, multicenter, double-blind, randomized, active-controlled clinical trial comparing the effects of the insulin sensitizer RSG with an insulin secretagogue, glipizide, on the progression of coronary atherosclerosis. Patients with type 2 diabetes and coronary artery disease undergoing clinically indicated coronary angiography or percutaneous coronary intervention are randomized to receive RSG or glipizide for 18 months using a glycemic titration algorithm designed to provide comparable glycemic control between treatment groups. The primary endpoint is the change in percent atheroma volume from baseline to study completion in a non-intervened coronary artery, as measured by intravascular ultrasound (IVUS). Cardiovascular events are adjudicated by an Endpoint Committee and patient safety monitored by an Independent Data Monitoring Committee. Results: A total of 672 patients were randomized to double-blind treatment at 92 centers in 19 countries. At baseline, mean age was 61 years, HbA1c 7.2%, body mass index 29.5 kg/m 2 , and median duration of diabetes 4.8 years. The majority of patients were receiving oral antidiabetic monotherapy (53.9%) at baseline, with 27.5% receiving dual-combination therapy and 17.9% treated with diet and exercise alone. Sixty-eight percent of patients had dyslipidemia, 79.9% hypertension, and 24% had a prior myocardial infarction. Follow-up IVUS examinations are expected to be completed in Summer 2008, with study results available for presentation at AHA Scientific Sessions. Conclusions: The APPROACH trial has enrolled the largest cohort of high-risk patients with type 2 diabetes of any IVUS study. APPROACH will compare the glucose-independent effects of RSG with glipizide on the progression of coronary atherosclerosis and provide additional data on the cardiovascular safety of RSG in patients with type 2 diabetes and coronary artery disease.
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A Novel Family-Based Intervention Trial to Improve Heart Health (FIT Heart): Results of a Randomized Controlled Trial
Lori Mosca, Heidi Mochari, Ming Liao, Allison H Christian, Dana J Edelman, Brooke Aggarwal, Mehmet C Oz; Columbia Univ Med Cntr, New York, NY Family members of patients with CVD may be at increased risk due to shared genes and lifestyle. We hypothesized that hospitalization for CVD may represent a "motivational moment" for family members to take preventive action. The purpose of this NHLBI sponsored 1yr randomized controlled trial was to test the effectiveness of a novel systems approach to screen and educate family members about lifestyle at the time of hospitalization for CVD to improve adherence to prevention goals. Methods: Participants were adult family members (Nϭ501, 66% female, 36% non-white, mean age 48 yrs) of patients admitted with atherosclerotic CVD. Subjects were eligible for the primary prevention of CVD and were excluded if they were diabetic or pregnant. Individuals were randomized to a special intervention (SI) that received personalized risk factor screening and therapeutic lifestyle change (TLC) diet/exercise counseling by non-physician, non-nurse health educators at regular intervals for 1yr or to the control intervention (CI) that received a general health message at baseline and only critical values for risk factors. Standardized CVD risk factors were obtained on all subjects at baseline and 1yr by research assistants blind to group assignment (94% follow-up). Lipids were measured in the Columbia University CTSA Biomarker Laboratory. Diet was assessed by the validated Block 98 and MEDFICTS Questionnaires. Results: There was significant improvement in the SI vs CI group in the mean % change in MEDFICTS diet score from baseline to 1 year (pϭ.04, difference ϭ 13.4%) and both groups showed significant improvements in saturated fat, dietary cholesterol, trans fat intake, LDL-C, and physical activity. HDL-C significantly decreased in the CI group but not the SI group, and the mean % change in HDL-C from baseline to 1 yr was significantly increased in the SI vs CI group (pϭ.01, difference 3.5%). The SI subjects were more likely to exercise Ͼ3 days per week compared to controls at 1yr (pϭ.04). Conclusion: A timely, targeted, low cost educational intervention was successful in improving lifestyle and HDL-C beyond several lifestyle improvements made in controls. Hospitalization of a family member with CVD is a unique motivational and educational opportunity to lower individual CVD risk. Objectives: Deficiency of the cardiac sarcoplasmic reticulum ATPase pump (SERCA2a) represents a common abnormality in the decline of cardiac contractile and relaxation function in HF. In preclinical studies, restoration of this enzyme via gene transfer utilizing a rAAV1 viral vector (AAV1/SERCA2a) was well tolerated and resulted in significant improvement in cardiac function and energetics. The present study is designed to investigate safety and effects of AAV1/SERCA2a on cardiac performance, LV remodeling and functional status in subjects with advanced HF. Methods: 9 class III/IV HF subjects (EF Յ30%) on maximal medical therapy with baseline anti-AAV1 neutralizing antibody (NAb) titers of Յ1:2 received intracoronary artery infusion of AAV1/SERCA2a. One of the following single doses was administered in an open-label dose-escalation manner: 1.4 x 10 11 , 6 x 10 11 , or 3 x 10 12 DNase Resistant Particles. Subjects had ICDs (and CRTs if indicated). Safety and efficacy assessments were scheduled at 3, 6, 9 & 12 months. Results: We present 6-month follow-up data for subjects in Cohorts 1&2 in the table (clinically meaningful changes are underlined). AAV1/SERCA2a demonstrated an acceptable safety profile in these advanced HF subjects. The subject in Cohort 1 with baseline NAbϭ1:2 failed to improve and went on to receive heart transplant. In contrast, significant improvement was observed in all NAb negative (Ͻ1:2) subjects with 4 of 5 having a decrease of 1 NYHA Class, as well as improvement in a number of other functional parameters. Conclusions: AAV1/SERCA2a resulted in an acceptable safety profile in subjects with advanced HF. Clinically meaningful improvements in functional status and/or cardiac function were observed in most subjects receiving AAV1/SERCA2a. Although the number of subjects in each cohort is too small to conduct statistical analyses, quantitative evidence of biological activity could be detected in a number of subjects following gene transfer. Introduction: There is evidence to suggest that recombinant activated factor VII (rFVIIa) can reduce intractable bleeding following cardiac surgery for patients who do not respond to standard treatment.We hypothesize that rFVIIa is safe and beneficial for use in patients undergoing cardiac surgery at high risk of bleeding. Methods: In a global trial, 172 patients who had undergone cardiac surgery and were bleeding were randomized to receive placebo (Nϭ68), 40 mcg/kg rFVIIa (Nϭ35), or 80 mcg/kg rFVIIa (Nϭ69) as a single bolus in an ICU setting. The primary endpoint was the number of patients suffering critical serious adverse events (cSAEs) at 30 days. Secondary endpoints included rates of re-operation, blood loss volumes and transfusion of allogeneic blood. Results: There were numerically more cSAEs in the rFVIIa groups (40 mcg/kg 14%, pϭ0.25; 80 mcg/kg:12%, pϭ0.43) than in placebo group (7%). Despite the numerical increase of cSAEs in the rFVIIa groups, the unadjusted and adjusted log Odds Ratios for cSAEs were statistically similar to the placebo group. Age (PϽ0.05), cardio-pulmonary bypass duration (PϽ0.05) and type of surgery (emergent/urgent) (PϽ0.001) were statistically significant predictors of cSAEs. Significantly fewer patients in the rFVIIa group underwent re-operations for bleeding {placebo:25%; 40 mcg/kg rFVIIa:14% [Pϭ0.21]; 80mcg/kg rFVIIa:12% [pϭ0.04]} and had smaller allogeneic blood transfusion volumes { placebo:825 mL [25%-75% IQR: 326.5-1893]; 40 mcg/kg rFVIIa:640 mL, Pϭ0.047 [25%-75% IQR: 0 -1920] ; 80mcg/kg rFVIIa: 500 mL, Pϭ0.042 [25%-75% IQR: 0 -1750]}. Four hours after randomization and drug administration the median drainage rate in the 80mcg/kg rFVIIa was significantly slower (24 mL/hr, Pϭ0.018; 25%-75% IQR: 13.3-32.0) than in the placebo (51 mL/hr; 25%-75% IQR: 21.3-82.7) and 40mcg/kg rFVIIa treatment groups (35 mL/hr, Pϭ0.763; 25%-75% IQR: 26.7-85.3). There was an approximately 50% reduction in the drainage volume within the 4 hours after treatment with 80mcg/kg rFVIIa (PϽ0.001) compared with placebo. Conclusions: On the basis of this preliminary prospective randomized trial it may be cautiously concluded that rFVIIa is probably safe and may be beneficial to treat bleeding after cardiac surgery.
Translational Trials and Strategies: First in Man
Three Months of Treatment with 5-Lipoxygenase Inhibitor VIA-2291 in Patients with Recent Acute Coronary Syndrome
Jean-Claude Tardif, Philippe L L'Allier, Reda Ibrahim, Jean C Gregoire, Montreal Heart Institute, Montreal, Canada; Andrew Hegedus, John Franc, John Blue, Melisa Cooper, VIA Pharmaceuticals, Princeton, NJ; Adeoye Olukotun, Montreal Heart Institute, Montreal, Canada; Rebecca Taub; VIA Pharmaceuticals, Princeton, NJ Background: There are currently no medications available to directly treat underlying inflammation of the blood vessel wall that can lead to plaque rupture and MI, ACS and stroke. Production of leukotrienes by 5-Lipoxygenase (5-LO) has been linked to atherosclerosis and plaque instability in humans and animal models. VIA-2291 is a potent 5-LO inhibitor that was previously studied in approximately 1100 patients in clinical trials for asthma. The purpose of this study was to test whether inhibition of 5-LO by VIA 2291 in a dose ranging, double blind study in ACS patients would demonstrate safety and efficacy in inhibiting 5-LO, and provide some insight into VIA 2291 effect on inflammatory biomarkers related to CAD. Methods: 191 patients 3 weeks after an ACS event were randomized to receive 25, 50, 100 mg VIA-2291 qd or placebo qd for 3 months. The primary endpoint was whole blood LTB4 (a measure of leukotriene biosynthesis) measured at trough drug level; secondary endpoints were urine LTE4 and serum hsCRP; and tertiary endpoints were other serum inflammatory biomarkers. Biomarkers were assessed by treatment group at baseline and weeks 2, 6, and 12. Results: Based on still blinded study population, baseline characteristics included age 37 -79 years (med 57, SD 9.7); 84% male / 16% female; BMI range 17.2 -46 (med 30, SD 4.8); presenting ACS event 45% STEMI/ 31% non-STEMI/ 24% UA; 90% PCI for presenting ACS event. Risk factors included 54% with history of hypertension; 17% prior MI; 20% prior PCI;17% diabetic. Concomitant medications: 95% HMGCoA reductase inhibitors; 97% platelet inhibitors (91% ASA / 91% clopidogrel); 84% beta blocker; 65% ace inhibitor; 17% A-II antagonist. VIA-2291 was generally well-tolerated. ϳ11% of patients had SAEs, of these ϳ 50% were cardiovascular, none of which were considered related to study drug. TEAEs were generally mild to moderate, the majority considered unrelated to treatment. hsCRP was elevated at baseline to 3-5 mg/L consistent with a post-ACS population. Conclusion: This study in post-ACS patients was designed to test the ability of VIA-2291 to inhibit leukotriene production in a dose-related fashion, and provide initial insight into the ability of VIA-2291 to reduce CAD associated inflammatory serum biomarkers such as hsCRP. Production of leukotrienes by 5-Lipoxygenase (5-LO) has been linked to atherosclerosis and plaque instability in humans and animal models. VIA-2291 is a potent 5-LO inhibitor that was previously studied in 1100 patients. The purpose of this study was to test whether inhibition of 5-LO would demonstrate anti-inflammatory effects in plaque tissue surgically removed from patients undergoing carotid endarterectomy (CEA), assess safety, mechanism of action and serum inflammatory biomarkers in this target population. Methods: 50 patients with significant carotid artery stenosis (60 -90%) were treated for three months with 100 mg qd of VIA-2291 or placebo in a Phase 2, double blind, randomized study. Patients were clinically stable and asymptomatic at randomization. The primary endpoint was plaque macrophage density (CD68); secondary endpoints included plaque 5-LO, whole blood LTB4, urine LTE4 and serum hsCRP. Results: Baseline characteristics were well balanced between treatment groups in the evaluable population with a median age of 68 (56 -82), 57% diabetics and 49% with hsCRP Ͼ2.0 mg/L. VIA-2291 was generally well-tolerated. There were no serious or unexpected drug-related adverse events. Carotid plaques from patients treated with VIA-2291 100mg qd for 12 weeks showed no difference in the mean % area of macrophages (Placebo: 7.63 ϩ/-7.1%; VIA-2291: 8.17ϩ/-5.96 %; pϭ0.84, nϭ25) and 5-LO immunostaining (Placebo: 0.84 ϩ/-1.26; VIA-2291: 1.79ϩ/-3.27; pϭ0.35, nϭ25) when compared to placebo. A significant reduction from baseline was observed for whole blood LTB4 production (pϽ0.001) and hsCRP (pϭ0.008) measured at 12 weeks. Urine LTE4 was significantly lower during the entire treatment phase in the group receiving 100mg VIA-2291 (Baseline pϭ0.42, pϽ0.0017 at Week 2, 6 & 12) . Conclusions: Administration of 100mg daily of VIA-2291 for 12-weeks significantly reduces systemic inflammatory biomarkers including hsCRP in patients undergoing CEA, while exhibiting a good safety profile. Significant changes in plaque inflammatory markers might not be observed for a number of reasons including: small sample size, high variability in plaque type and the high number of relatively stable plaques expected and subsequently found in these asymptomatic patients.
Gene Evaluation for ANtihypertensive Effect of drugs (GEANE): A Multicenter Trial
Kei Kamide, Hironori HanadaNatl Cardiovascular Ctr, Suita City, Japan; , Natl Cardiovascular Ctr, Suita, Japan; Tosiyuki Miyata, Akiko Kada, Natl Cardiovascular Ctr, Suita City, Japan; Shinto Eguchi, Toshiharu Fujita, Institute of Statistical Mathematics, Tokyo, Japan; Kazuhiro Sase, Juntendo Univ, Tokyo, Japan; Hitonobu Tomoike, Yuhei Kawano, geane Study Group; Natl Cardiovascular Ctr, Suita City, Japan Aim: Prediction of antihypertensive effect of drugs based on genetic variation is supposed to be most desirable in individualized treatment of hypertension. The aims of this study are to clarify susceptible single nucleotide polymorphisms (SNPs) to angiotensin II receptor blockade (ARB; Valsartan), calcium channel blockade (CCB; Amlodipine) and thiazide type diuretics (DU; Indapamide) and to establish the way to predict the most effective drug based on these SNPs information in each individual. Methods: This study is a multi-center trial with the prospective randomized crossover design. Patients with untreated mild to moderate essential hypertension were recruited. After a control period for one month, each of antihypertensive three drugs was administrated. In each drug period, subjects took a half dose of ARB or CCB or DU for one month and regular dose for two months. Total study period was ten months. The cut-off definition of drug responder was investigated by several values including Ͻ140/90mmHg, systolic blood pressure (SBP)Ͻ-10 or -20mmHg and treated BP adjusted by baseline BP. DNA analysis was performed by Affymetrix 500K DNA micro-array chips. Results: Finally, 134 subjects (Male: 73) completed all study protocol and genetic analysis. Averaged BP was 156Ϯ13/94Ϯ10mmHg at the control period, and three drugs significantly reduced BP similarly (ARB: 135Ϯ14/84Ϯ10, CCB: 133Ϯ12/83Ϯ9, DU: 134Ϯ14/84Ϯ10). 39 subjects had obtained target BP (Ͻ140/90mmHg) by all three drugs, however, 21 subjects did not obtain target BP by any drugs. Nine had below target BP only by ARB, 10 had it only by CCB and 9 had below target BP only by DU. 386506 SNPs selected by HWE Ͼ0.01 and MAF Ͼ0.01 were analyzed. There were 18000 -20000 statistical significant SNPs (pϽ0.05) for each single drug using several cut-off values, and 2000 -3000 SNPs associated with two drug response and 300 -400 SNPs associated with all three drug response. Minimum p value range was about 10 -8 -10 -6 . Conclusion: There are some susceptible SNPs to BP response of three important antihypertensive drugs. Although the validation of reproducibility of these SNPs is necessary, our strategy would be useful to establish prediction of the best drug based on SNPs information in individualized treatment of hypertension. In healthy subjects CK-452 increases systolic ejection time (SET), stroke volume (SV), fractional shortening (FS), and ejection fraction (EF). We sought to extend these findings in 2 -72 hr infusions in stable heart failure (HF) patients. Methods: This first Phase II trial of CK-452 is a multi-center, double-blind, randomized, placebo-controlled study in patients with EF Ͻ 40% and treated with stable HF medication. In Cohorts 1-4, patients received 3 escalating i.v. doses of CK-452 and 1 placebo treatment, randomized into the dosing sequence. Infusions were 2 hrs in Cohorts 1&2 and 24 hrs in Cohorts 3&4. Cohort 5 investigates 72 hr infusions as a two-period placebo-controlled crossover with a target plasma concentration of 650 ng/ml. Results: In analyses of data from 28 completed patients in Cohorts 1 to 4, echocardiographic data were paired with coincident plasma concentrations of CK-452 to perform a PK/PD analysis. Statistically significant concentration dependence was observed for increases in EF and decreases in heart rate and left ventricular end systolic volume. The significance of increases in EF differed between methods of calculation. Treatments were well tolerated at pre-specified dosages. Results from Cohorts 1 to 4 and initial results from the 72 hr exposure will be available at the time of presentation. Conclusions: CK-452 appears to be well tolerated and increases systolic function in stable HF patients during intravenous administration. Data from this first Phase II trial may support translation of this novel mechanism into populations with more advanced heart failure. by 8 months. The secondary endpoint was a composite of major adverse cardiac events (myocardial infarction, and ischemia-driven revascularization of the target lesion) by 12 months. Results: The clinical and angiographic baseline characteristics were similar in both examined groups. At 8 months angiographic follow up the minimal luminal diameter in stent was significant larger with SES as compared to PES (2.58Ϯ0.04 mm vs. 2.45Ϯ0.04 mm, pϭ0.025). The rates of angiographic restenosis were 9.2Ϯ1.3% using SES as compared to 14.1Ϯ1.3% of the PES (pϭ0.011). Late luminal loss in stent was significantly less using SES as compared to PES (0.13Ϯ0.03 mm vs. 0.26Ϯ0.04 mm, pϭ0.011). At 12 months, clinical event were not different in the two groups with regard to the secondary endpoint (SES group: 5 events, PES group: 3 events). By intra-individual comparison three different patterns were present: (1) patients with comparing restenosis in both stents, (2) patients with restenosis predominantly within the SES, and (3) patients with restenosis predominantly within the PES. Conclusion: In this first intra-individual comparison the use of SES resulted in a lower rate of angiographic in stent restenosis as compared with the PES. Clinical course was found not to be different at 12 months. While some observational studies have suggested an association between the two conditions, recent randomized trials of PFO closure in migraine patients have been negative. We sought to evaluate the association between migraine headaches and the presence of PFO in a large case-control study. Methods: We conducted a case-control study with prospective data collection to assess the prevalence of PFO in subjects with and without migraine. Cases (Nϭ158) were those with a history of migraine (diagnosed by neurologists at a headache clinic in a major academic hospital). Controls (Nϭ156), healthy volunteers without migraine, were 1:1 matched on age and sex with cases. To avoid enrollment of subjects with risk for PFO other than migraine alone, subjects with known history of cerebrovascular disease, paradoxical embolism or decompression illness were excluded. Presence of PFO was determined using transthoracic echocardiogram with second harmonic imaging and transcranial Doppler ultrasonography, both using agitated saline contrast Ϯ Valsalva maneuver, and performed and reported with blinding to case-control status. PFO was considered to be present if both studies were positive. Odds ratios (OR) were calculated using conditional logistic regression in the matched cohort (Nϭ288). Results: Cases (Nϭ144) and controls (Nϭ144) were well balanced with respect to matching factors (mean age, 41.6 vs. 41.4; females, 83% both cohorts). Migraine with aura was present in 39% of cases. In the matched analysis, the prevalence of PFO was similar in cases and controls (26.4% vs. 25.7%; OR 1.04, 95% CI: 0.62-1.74, pϭ0.90). There was no difference in PFO prevalence in those with migraine with aura or those without (26.8% vs. 26.1%; OR 1.03, 95% CI: 0.48 -2.21, pϭ0.93). Multivariable analysis identified family history of migraine as the strongest independent predictor of migraine (OR 21.16, 95% CI: 7.4 -60.5, pϽ0.001) followed by family history of cerebrovascular disease (OR 2.78, 95% CI 1.19 -6.49, pϭ0.02). PFO was not predictive of migraine (pϭ0.18). Conclusion: We found no association between migraine headaches and the presence of patent foramen ovale in this large case-control study.
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Intracoronary Infusion of Mononuclear Cells After Primary Percutaneous Coronary Intervention: The HEBE Trial
Background: Remote monitoring (RM) of ICDs may provide daily, automatic device and patient status data and cardiac event notifications. TRUST tested the hypothesis that RM was safe and effective for ICD follow-up for 1 year in a prospective, randomized controlled clinical trial. Methods: 1282 patients were randomized 2:1 to RM or to conventional (RM disabled) groups. Follow up checks occurred at 3, 6, 9, 12 and 15 months post-implant. In the RM arm, RM was used before office visits (OVs) at 3 and 15 months. At 6, 9 & 12 months, RM only was used but followed by OVs if necessary. Conventional patients were evaluated with OVs only. Follow up was "actionable" if system reprogramming/revision or change in anti-arrhythmic therapy occurred. Scheduled and unscheduled OVs (including responses to event notifications in RM) were quantified for each individual patient per year (pt yr) of follow up. Incidence of death, strokes and surgical interventions (morbidity) was tracked in both groups. Results: RM and conventional patients were similar in age (63.3 Ϯ 12.9 vs 64.1 Ϯ 12.0 yrs, p ϭ 0.30), gender (71.9% vs 72.4% male, p ϭ 0.89), pathology (LVEF 29.1 Ϯ 10.8% vs 28.6 Ϯ 9.8%, p ϭ 0.47; coronary artery disease 64.5% vs 71.4%, p ϭ 0.02), medications (␤ blockers 79.5% vs 75.9%, ACE inhibitors 42.4% vs 46.8%, ARBs 7.8% vs 9.9%, p ϭ NS), indication (primary prevention 72.3% vs 74.2%, p ϭ 0.50), and dual chamber implants (57.9% vs 57.0%, p ϭ 0.76). RM reduced scheduled OVs by 54% and total OVs by 42% without affecting morbidity. Event notifications were managed using RM alone in 92% of cases. Of the remainder resulting in unscheduled OVs, 52.2% were actionable. RM improved adherence to follow-up. Conclusions: TRUST demonstrated that remote monitoring is safe, decreases the need for in-office visits, provides early detection of significant problems, and improves ICD surveillance without increasing unscheduled office visits. In conclusion, remote monitoring is a safe alternative to conventional care. 
Background:
The role of catheter ablation (CA) for treatment of paroxysmal atrial fibrillation (AF) remains incompletely defined. A prospective multicenter randomized trial (NCT 00116428) was designed to test the effectiveness of the Navistar Thermocool Radiofrequency Ablation Catheter (Biosense Webster, Diamond Bar CA) compared to antiarrhythmic drug (AAD) therapy in this population. Methods: The trial was conducted in 19 centers. Enrollment criteria included Ͼ 3 symptomatic episodes of paroxysmal AF (at least one ECG verified) within the 6 mo prior to randomization, and failure with at least one AAD or AV nodal blocking agent. Pts with AF Ͼ 30 days in duration, age Ͻ 18, or ejection fraction Ͻ 40% were excluded. Pts were randomized 2:1 to CA or a previously untested class I or III AAD, and were followed for one year. CA included pulmonary vein isolation with electrophysiologically confirmed entrance block as the endpoint in all pts. In pts randomized to CA, chronic efficacy was evaluated after a 3 mo blanking period. In pts randomized to AAD, chronic efficacy was evaluated after a 2 week dose titration period. All pts underwent transtelephonic monitoring via an independent core laboratory throughout follow-up during any symptoms; additional transmissions irrespective of
